Answers are grounded in this paper and cite their sources.
Editor—We read with interest the work of Fenger-Eriksen and his colleagues,1Fenger-Eriksen C Lindberg-Larsen M Christensen AQ Ingerslev J Sørensen B Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations.Br J Anaesth. 2008; 101: 769-773Abstract Full Text Full Text PDF PubMed Scopus (202) Google Scholar regarding fibrinogen concentrate substitution therapy in patients with massive haemorrhage and hypofibrinogenaemia. The authors reported an improvement of varying significance in the serum clotting tests and recommended further prospective work to further evaluate the haemostatic potential of fibrinogen. As our understanding of coagulocompetence and our knowledge of the interaction between the serine protease cascade, platelet activation, and the role of fibrinolysis, increases,2Brohi K Cohen M Ganter MT Matthay MA Mackersie RC Pittet JF Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway?.Ann Surg. 2007; 245: 812-818Crossref PubMed Scopus (631) Google Scholar we require a test that reflects overall coagulation status to individualize blood component prescription. With the increasing use of platelets and haemostatic resuscitation3Holcomb JB Jenkins D Rhee P et al.Damage control resuscitation: directly addressing the early coagulopathy of trauma.J Trauma. 2007; 62: 307-310Crossref PubMed Scopus (965) Google Scholar to treat massive haemorrhage, plasma tests could be increasingly misleading. It is our opinion that thromboelastometry (ROTEM) and thromboelastography (TEG) would be best suited to measure coagulocompetence in future studies, where coagulation factor depletion and fibrinolysis may be a significant contributor to any perceived coagulopathy. These techniques would allow accurate monitoring of whole blood coagulation in a wide range of conditions, where typically, serum tests, prothrombin time (PT), and activated partial thromboplastin time (APTT) may not be as sensitive. During progressive blood loss, TEM and TEG provide point of care testing and are easily interpreted with minimal delay, differentiating between a functional loss in factors, platelets, or fibrinogen or indeed demonstrating hyperfibrinolysis. Such tests are a safe and cost-effective4J Craig, R Aguiar-Ibanez, S Bhattacharya, The Clinical and Cost Effectiveness of Thromboelastography/thromboelastometry, HTA Programme: Health Technology Assessment Report 11.Google Scholar surveillance of coagulation, and expedite/assist with the most appropriate blood component therapy, thereby minimizing donor exposures and inappropriate blood bank stock use.5Johansson P Treatment of massively bleeding patients: introducing real time monitoring, transfusion packages and thrombelastography (TEG®).ISBT Sci Series. 2007; 2: 159-167Crossref Google Scholar, 6Spalding GJ Hartrumpf M Oesberg N Kirsche CG Albes JM Cost reduction of perioperative coagulation management in cardiac surgery: value of ‘bedside’ thromboelastography (ROTEM).Eur J Cardiothorac Surg. 2007; 31: 1052-1057Crossref PubMed Scopus (181) Google Scholar What do the authors feel would be the most appropriate test for coagulation in future studies? Editor—We thank Dr Moor and colleagues for their interest. Laboratory monitoring of haemostatic capacity in the setting of perioperative bleeding management is challenging. As outlined by Moor and colleagues, the overall haemostatic capacity depends on a concerted action of plasma pro-coagulant and anti-coagulant proteins and also platelets and other blood cells. In particular, in management of perioperative bleeding, bedside whole blood coagulation analysis such as TEG or ROTEM appear more rational modalities for assessing the overall haemostatic capacity than standard plasma tests. As briefly mentioned in our manuscript, in particular, standard laboratory measurement of levels of fibrinogen using the Clauss method may result in underestimating the importance of fibrinogen as a haemostatic agent in management of perioperative and traumatic haemorrhage.7Hiippala ST Dextran and hydroxyethyl starch interfere with fibrinogen assays.Blood Coagul Fibrinolysis. 1995; 6: 743-746Crossref PubMed Scopus (95) Google Scholar, 8Hellstern P Muntean W Schramm W Seifried E Solheim BG Practical guidelines for the clinical use of plasma.Thromb Res. 2002; 107: S53-S57Abstract Full Text Full Text PDF PubMed Scopus (75) Google Scholar There may be several reasons for fibrinogen concentrate being overlooked as potent haemostatic intervention. For decades, haematologists have set the lower threshold level of fibrinogen at 1 g litre−1. Unfortunately, this level has never been clinically validated, yet mentioned again and again, although a series of publications have indicated that the critical level of fibrinogen may be significantly higher. A majority of patients experiencing excessive bleeding are treated with colloid plasma expanders for volume substitution. The presence of colloid plasma expanders or high levels of fibrin degradation products has been reported to induce artificial false high levels of fibrinogen when measured by the Clauss method. These phenomena may further have masked the recognizing and understanding the importance of fibrinogen in management of perioperative/traumatic bleeding. Finally, the use of plasma expanders, such as colloids, gelatine, or dextrans, is now known to induce a coagulopathy characterized by acquired hypofibrinogenaemia and abnormal fibrin polymerization.9Fenger-Eriksen C Anker-Moller E Heslop J Ingerslev J Sorensen B Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate.Br J Anaesth. 2005; 94: 324-329Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar, 10Fries D Innerhofer P Klingler A et al.The effect of the combined administration of colloids and lactated Ringer's solution on the coagulation system: an in vitro study using thrombelastograph coagulation analysis (ROTEG).Anesth Analg. 2002; 94: 1280-1287Crossref PubMed Scopus (127) Google Scholar, 11Mittermayr M Streif W Haas T et al.Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration.Anesth Analg. 2007; 105 (table): 905-917Crossref PubMed Scopus (238) Google Scholar Moreover, experimental studies, animal studies, retrospective clinical surveys, and prospective randomized clinical studies have demonstrated excellent haemostatic effect of substitution with a fibrinogen concentrate.1Fenger-Eriksen C Lindberg-Larsen M Christensen AQ Ingerslev J Sørensen B Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations.Br J Anaesth. 2008; 101: 769-773Abstract Full Text Full Text PDF PubMed Scopus (202) Google Scholar, 9Fenger-Eriksen C Anker-Moller E Heslop J Ingerslev J Sorensen B Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate.Br J Anaesth. 2005; 94: 324-329Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar 12Fries D Krismer A Klingler A et al.Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model.Br J Anaesth. 2005; 92: 172-177Abstract Full Text Full Text PDF Scopus (163) Google Scholar, 13Danes AF Cuenca LG Bueno SR Mendarte BL Ronsano JB Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding.Vox Sang. 2008; 94: 221-226Crossref PubMed Scopus (113) Google Scholar Haemostatic functional levels of fibrinogen can be evaluated by TEG or ROTEM using commercially available tests, such as the FibTEM® or Functional fibrinogen® test. In contrast to standard Clauss measurements, the FibTEM test (and likely also the Functional fibrinogen test) has been shown to clearly reveal abnormal fibrinogen after haemodilution. In conclusion, we agree with Moor and colleagues that systematic bedside use of TEG or ROTEM will induce a more rational use of blood products and guide in selection of effective coagulation factor concentrates. In particular, the fibrinogen-sensitive assays seem important to early recognize acquired fibrinogen deficiency.
No takes yet. Share an insight, caveat, or question.
Moor et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: